Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Bogard

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Pediatric Emergency Care|August 5, 2016
Diagnosis of Cystic Teratoma Facilitated by Point-of-Care UltrasonographyKimberly Bogard Horner, Jennifer R Marin
Neurorehabilitation and Neural Repair|March 12, 2009
Can the Wolf Motor Function Test be streamlined?Kimberly Bogard, Steven Wolf, Qin Zhang, et al.
In Vivo (Athens, Greece)|November 16, 2014
IL6 plasma concentrations in patients with sepsis receiving SLED and antibiotics: a predictor for survivalTimothy R McGuire, Nicole T Reardon, Kimberly Bogard, et al.
Future Oncology (London, England)|October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myelomaRobert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Pediatric Emergency Care|August 5, 2016
Diagnosis of Cystic Teratoma Facilitated by Point-of-Care UltrasonographyKimberly Bogard Horner, Jennifer R Marin
Neurorehabilitation and Neural Repair|March 12, 2009
Can the Wolf Motor Function Test be streamlined?Kimberly Bogard, Steven Wolf, Qin Zhang, et al.
In Vivo (Athens, Greece)|November 16, 2014
IL6 plasma concentrations in patients with sepsis receiving SLED and antibiotics: a predictor for survivalTimothy R McGuire, Nicole T Reardon, Kimberly Bogard, et al.
Future Oncology (London, England)|October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myelomaRobert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Pageof 1